CRIT peptide interacts with factor B and interferes with alternative pathway activation |
| |
Authors: | Hui Kwok-Min Magnadóttir Bergljót Schifferli Jürg A Inal Jameel M |
| |
Affiliation: | University Hospital Basel, Immunonephrology, Department of Research, Hebelstrasse 20, CH-4031 Basel, Switzerland. 12min@mail.hongkong.com |
| |
Abstract: | Complement C2 receptor inhibitor trispanning (CRIT) inhibits the classical pathway (CP) C3 convertase formation by competing with C4b for the binding of C2. The C-terminal 11-amino-acid of the first CRIT-extracellular domain (CRIT-H17) has a strong homology with a sequence in the C4beta chain, which is responsible for the binding of C2. Since the CP and alternative pathway (AP) C3 convertases have many functional and structural similarities, we further investigated the effects of CRIT-H17 on the AP. The factor D-mediated cleavage of factor B (FB) was blocked by CRIT-H17. By ELISA and immunoblot, CRIT-H17 was shown to bind FB. CRIT-H17 had no decay activity on the C3bBb complex as compared to decay-accelerating factor. Binding of CRIT-H17 to FB did not interfere with the assembly of C3bB complex. In a haemolytic assay using C2-deficient serum, CRIT-H17 interfered with AP complement activation. |
| |
Keywords: | Alternative pathway Factor B Complement C2 receptor inhibitor trispanning C3 convertase Haemolytic assay Factor D |
本文献已被 ScienceDirect PubMed 等数据库收录! |